2025 Recap: Your Favorite Alira Health Publications
In 2025, our expert thought leadership delved into pivotal shifts and trends across industries, therapeutic areas, and modalities and emphasized the essential role of patient engagement across the product lifecycle. We explored and discussed the forces reshaping the healthcare ecosystem, and what they mean for manufacturers and patients. This page features the standout reports, white papers, and interviews published throughout the year.
Report
The 2025 Global Medtech Contract Development and Manufacturing Report
The 2025 edition of our CDMO medtech report provides data-driven insights into how outsourcing partners are reshaping the medtech innovation ecosystem.
Want more CDMO medtech insights? View the webinar Driving Competitive Advantage: How CDMOs Are Powering Medtech Innovation to learn how medtech companies and CDMOs can balance risk and opportunity in a rapidly shifting environment.
Report
The 2025 Biologics Contract Manufacturing Report
Discover a comprehensive analysis of the global rebound in biologics outsourcing following a year of macroeconomic headwinds and market contraction. This report provides insights into the CDMO biologics landscape, covering manufacturing demand, regional investment, and therapeutic innovation across biologic therapies, including protein-based therapies, non-protein vaccines, and advanced therapies.
Report
The 2025 Global Drug Delivery System Trends Report
This report highlights the structural transformation of the global DDS market, including how digital integration, sustainability goals, patient-centric design, rising demand for large-volume subcutaneous delivery, and off-the-shelf platform solutions are reshaping pharma strategies and the DDS value chain. It provides strategic insights to help pharmaceutical companies, device manufacturers, CDMOs, and investors navigate this dynamic and fast-growing sector.
White Paper
Nuclear Medicine in 2024: A Year of Breakthroughs and Challenges
This white paper reviews key trends from 2024 into 2025. It includes breakthroughs in radiopharmaceutical development and clinical advances, investment activity, challenges impacting growth and innovation, and expert predictions for 2025—discover if they came true!
White Paper
Navigating the Evolving Global Nuclear Medicine Supply Chain in 2025 and Beyond
This white paper provides a full break down of the nuclear medicine supply chain—from isotope production to patient delivery—and uncovers the pressure points impacting radioligand therapies growth. It also outlines a five-part strategy framework for stakeholders to strengthen supply chain resilience, optimize manufacturing networks, and navigate the complex reimbursement landscape.
Report
The 2025 Global Biosimilars Report
This report provides an assessment of trends in the global biosimilars market, with an emphasis on market and competitive dynamics in the US and Europe. It offers insights on market growth, regional dynamics, key players, M&A activity, licensing trends, market-shaping partnerships, and growth outlook.
Article
New Regulation on Health Technology Assessment Impact in France
This article provides an overview of how France is adapting to the new EU HTAR and what it means for market access. It outlines how national processes are evolving under the European framework, and highlights which elements are likely to change—and those that will remain unchanged—following the introduction of the HTAR.
Case Study
Pharma Company Defines Advocacy Strategy Through Data-Driven Patient Association Mapping
Our Patient Experience team delivered a comprehensive, data-driven assessment of the cardiovascular, renal, and metabolic patient advocacy groups landscape, enabling the client to make strategic, well-informed partnership decisions. The insights generated guided a focused advocacy strategy, helping prioritize high-impact collaborations and strengthen patient support and policy influence.
Interview
Rethinking Rare Disease Development: An Integrated, Patient Access-Driven Approach
In rare disease there is no clear boundary between development and commercialization—commercial success is built early by placing patient access at the core of strategy. In this interview, Joris Pezzini, EVP Biopharma, explores how biotech companies can succeed in rare disease by integrating development, commercialization, and patient access.
Interview
From Diagnosis to Long-Term Care: Navigating the Rare Disease Journey
The patient journey spans from the first signs of illness through long-term care. For rare disease patients, this journey presents significant and unique challenges. In this interview, patient engagement expert, Luca Trentin, discusses these challenges and outlines the steps pharma companies can take to better understand and address patients’ needs.
Subscribe to our newsletter for the latest news, events, and thought leadership